Hyperfine, Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop Portable MR Imaging System
Latest Swoop software improves image quality for DWI imaging of the brain
Hyperfine, the groundbreaking medical device company that created the Swoop system, the world’s first FDA-cleared portable magnetic resonance imaging (MRI) device for imaging of the brain, announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the company’s upgraded AI-powered software.
Latest Aithority Insights : Lion Announces It Will Explore ChatGPT Related AI & NLP Technologies To Empower Digital Program
The most recently cleared Swoop software improves the image quality of the diffusion-weighting imaging (DWI) sequence with increases in its signal-to-noise ratio. An additional update in this software release increases the Swoop Portable MR Imaging System field of view by 10% for T1, T2, and FLAIR sequences to match the previously improved DWI sequence’s 20cm field of view. Field of view size is important for visualizing pathology deep in the brain.
“The latest Swoop software improves image quality with notable improvement in the appearance of the DWI images. The improved image quality more clearly displays underlying brain structure, further accentuating diffusion positivity and potentially increasing confidence in image interpretation and clinical decision-making,” said Edmond Knopp, M.D., senior medical director of Hyperfine, Inc.
“Our team continues to make rapid and significant software advancements for our first-in-class ultra-low-field Swoop Portable MR Imaging System to deliver diagnostic-quality brain images that enable timely clinical decision-making at the point of care,” said Maria Sainz, president and CEO of Hyperfine, Inc. “We are committed to continuous improvement to optimize the clinical utility of the Swoop system while driving commercial adoption across leading institutions globally. We have released two new sequences (T1 Standard and Fast T2) in the last twelve months, improved DWI sequence image quality twice, and expanded the system’s field for view.”
Hyperfine, Inc. first received initial FDA clearance for the Swoop Portable MR Imaging System in 2020 and has received two additional FDA clearances for hardware improvements and seven clearances for upgraded software, including BrainInsight software—with five of these clearances received in 2022. Hyperfine, Inc. maintains a total installed base* of 100 Swoop systems globally, and twenty peer-reviewed clinical publications have included Swoop system data.
Recent AiThority News : Intermap Selected by the U.S. Department of Defense to Demonstrate Advanced AI/ML
“We’re investing heavily in software development, AI, and image quality and are committed to expanding the toolbox available to our users,” said Tom Teisseyre, chief product officer of Hyperfine, Inc. “These initiatives are core to our transformative approach to MR imaging, making it a reality for a growing number of patients in the fast-evolving diversity of sites of care.”
As of Hyperfine, Inc.’s third-quarter 2022 earnings report on November 10, 2022. The Swoop system total installed base consists of commercial system installations (which make up total revenue), grant fulfillment installations, and research unit installations. The Swoop system total installed base (or total installed units) is the number of Swoop® devices deployed to hospitals, other healthcare providers, and research institutions. We view the total installed base as a key metric of the growth of our business and is measured from period over period.
Hyperfine, is the groundbreaking medical technology company that created the Swoop system, the world’s first FDA-cleared portable magnetic resonance imaging (MRI) system capable of providing neuroimaging at the point of care. The Swoop system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a bedside magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, and is also available in New Zealand and Pakistan.
The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging, and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside.
NLP News: Mindsdb Raises $16.5Million From Benchmark to Put Machine Learning Into More Applications
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.